Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login

News

Featured Clinical Trial of the Week: Comparing Treatments for Relapsed Small Cell Lung Cancer

  • February 08 2013

    Share |
    Featured Clinical Trial of the Week: Comparing Treatments for Relapsed Small Cell Lung Cancer

    While many small cell lung cancer (SCLC) patients have success with their first rounds of treatment, some experience a relapse and see their cancer progress. When this happens, the tumor can be more difficult to treat, so researchers are working to determine which therapies are most likely to benefit patients.

    After experiencing a relapse, many patients undergo further rounds of chemotherapy with drugs like topotecan hydrochloride, but other therapies may also be effective. One such drug, called linsitinib, works by targeting and blocking IGF-1R, a molecule that can help tumors grow and spread. This clinical trial compares the effectiveness of these two drugs.

    Eligible for this study are patients with SCLC who have experienced a relapse after undergoing only one regimen of platinum-based chemotherapy. Visit ClinicalTrials.gov for further eligibility and enrollment information for this clinical trial.
 


    If you’re looking for information on other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.

    0 comments

Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2017 Free To Breathe | Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.